Drugs / NP2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00804076 | Feb 2008 → Nov 2010 | — | Diamyd Inc | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01291901 | Jan 2011 → Jul 2012 | neoplasm | Diamyd Inc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NP2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01291901 ↗ |
| Route | Other | “Intradermal injection of NP2 at doses ranging from 10e7 to 10e9 pfu at the site of pain” NCT00804076 ↗ |